sintaflat
laboratÓrio globo sa - adsorventes e antifiseticos intestinais simples
androsten
herbarium laboratorio botanico ltda - tribulus terrestris l. - fitoterapico simples; androgenos simples
clexane
sanofi-aventis farmacÊutica ltda - enoxaparina sÓdica - antitrombotico
etira
aché laboratórios farmacêuticos s.a - levetiracetam - anticonvulsivantes
etira
aché laboratórios farmacêuticos s.a - levetiracetam - anticonvulsivantes
heparinox
cristÁlia produtos quÍmicos farmacÊuticos ltda. - enoxaparina sÓdica - antitrombotico
keppra
ucb biopharma ltda. - levetiracetam - anticonvulsivantes
levetiracetam
eurofarma laboratÓrios s.a. - levetiracetam - anticonvulsivantes
volibris
glaxosmithkline brasil ltda - ambrisentana - anti-hipertensivos
ultomiris
alexion europe sas - ravulizumab - hemoglobinúria, paroxística - imunossupressores seletivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.